Affiliations 

  • 1 Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
  • 2 Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
  • 3 Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA; School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
  • 4 Mahidol University Health Technology Assessment Program, Mahidol University, Bangkok, Thailand
  • 5 Faculty of Pharmacy, University of Health Sciences, Vietnam National University Ho Chi Minh City, Vietnam
  • 6 Mahidol University Health Technology Assessment Program, Mahidol University, Bangkok, Thailand; Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Udayana University, Bali, Indonesia
  • 7 Mahidol University Health Technology Assessment Program, Mahidol University, Bangkok, Thailand; Department of Clinical, Social and Administrative Pharmacy, College of Pharmacy, University of the Philippines Manila, Manila, Philippines
  • 8 Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA; Department of Internal Medicine, Dell Medical School, The University of Texas at Austin, Austin, TX, USA
  • 9 Social and Administrative Pharmacy Division, Department of Pharmacy, Mahidol University, Bangkok, Thailand
  • 10 Keio Global Research Institute, Keio University, Tokyo, Japan
  • 11 Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA. Electronic address: Nathorn.chaiyakunapruk@utah.edu
Value Health, 2025 Feb 06.
PMID: 39922297 DOI: 10.1016/j.jval.2025.01.012

Abstract

OBJECTIVES: This landscape analysis aimed to summarize the role of health equity in health technology assessment (HTA) process (topic nomination, topic prioritization, assessment, appraisal, and decision-making) in Asia.

METHODS: A comprehensive literature review followed by in-depth interviews with key informants was conducted. Content analysis was performed to summarize the role of health equity in HTA in thirteen health systems in Asia, including Brunei Darussalam, Cambodia, China, Indonesia, Japan, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam.

RESULTS: Health equity was reported to be considered in most health systems' HTA process, except for Cambodia and Myanmar, which do not have an established HTA process. Interviews revealed that health equity has been more frequently considered to address the unmet medical needs of specific diseases (e.g., high disease burden or severity, rare diseases, cancer, and diseases affecting children and elderly) in Brunei Darussalam, China, Japan, Malaysia, Singapore, South Korea, Taiwan, Thailand, and Vietnam or inequities in the socially disadvantaged groups (e.g., socioeconomic status and geographical location) in Indonesia and the Philippines. Equity-informative economic evaluation was still in the early stages, with only three health systems reporting their use.

CONCLUSIONS: Health equity is considered in the HTA process in most Asian health systems. However, quantitative evaluation of health equity impact is still in its infancy as few health systems have just begun to perform equity-informative economic evaluations.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.